BACKGROUND AND AIMS: Vitamin D(3), in addition to its role in calcium homeostasis, has been recognized as playing a role in human cancer development. However, little is known about the association between vitamin D status and the development of thyroid cancer. This study aimed to investigate vitamin D metabolism by measuring 25(OH) D(3), 1-25 (OH)(2) D(3), PTH and calcium concentrations in the peripheral blood of patients with different forms of thyroid tumors. METHODS: The 25-hydroxyvitamin D(3) ,1-25- dihydoxyvitamin D(3), PTH and calcium serum levels of 50 consecutive patients with epithelial thyroid cancer 27 cases of papillary cancers (PTC), 16 follicular cancers (FTC), and seven cases of anaplastic cancers (ATC) and 34 multinodular nontoxic goiter (MNG) were measured by specific immunoassay. The control group consisted of 26 healthy volunteers. RESULTS: Our results revealed significantly lower 1-25 (OH)(2) D(3) concentration in the PTC group (22.67 pg/mL +/- 8.12; p <0.05), FTC group (16.09 pg/mL +/- 6.15; p <0.02) and ATC group (9.48 pg/mL +/- 5.18; p <0.02). Levels of 1-25 (OH)(2) D(3) varied by cancer stage and were also significantly different. A significant decrease in circulating 1-25 (OH)(2) D(3) concentration was found in patients with stage I (24.12 pg/mL +/- 6.77; p <0.05), stage II (16.93 pg/mL +/- 4.55; p <0.05), stage III (12.44 +/- 8.98; p <0.02) and in stage IVa (6.18 +/- 2.22; p <0.01). There were no significant differences when comparing serum levels of 25(OH) D(3), PTH or calcium concentrations among individuals with multinodular goiter, thyroid cancer and age- and sex-matched control volunteers. CONCLUSIONS: Our study revealed that impaired vitamin D(3) metabolism may play an important role in thyroid follicular cell oncogenesis. Copyright 2010 IMSS. Published by Elsevier Inc. All rights reserved.
BACKGROUND AND AIMS: Vitamin D(3), in addition to its role in calcium homeostasis, has been recognized as playing a role in humancancer development. However, little is known about the association between vitamin D status and the development of thyroid cancer. This study aimed to investigate vitamin D metabolism by measuring 25(OH) D(3), 1-25 (OH)(2) D(3), PTH and calcium concentrations in the peripheral blood of patients with different forms of thyroid tumors. METHODS: The 25-hydroxyvitamin D(3) ,1-25- dihydoxyvitamin D(3), PTH and calcium serum levels of 50 consecutive patients with epithelial thyroid cancer 27 cases of papillary cancers (PTC), 16 follicular cancers (FTC), and seven cases of anaplastic cancers (ATC) and 34 multinodular nontoxic goiter (MNG) were measured by specific immunoassay. The control group consisted of 26 healthy volunteers. RESULTS: Our results revealed significantly lower 1-25 (OH)(2) D(3) concentration in the PTC group (22.67 pg/mL +/- 8.12; p <0.05), FTC group (16.09 pg/mL +/- 6.15; p <0.02) and ATC group (9.48 pg/mL +/- 5.18; p <0.02). Levels of 1-25 (OH)(2) D(3) varied by cancer stage and were also significantly different. A significant decrease in circulating 1-25 (OH)(2) D(3) concentration was found in patients with stage I (24.12 pg/mL +/- 6.77; p <0.05), stage II (16.93 pg/mL +/- 4.55; p <0.05), stage III (12.44 +/- 8.98; p <0.02) and in stage IVa (6.18 +/- 2.22; p <0.01). There were no significant differences when comparing serum levels of 25(OH) D(3), PTH or calcium concentrations among individuals with multinodular goiter, thyroid cancer and age- and sex-matched control volunteers. CONCLUSIONS: Our study revealed that impaired vitamin D(3) metabolism may play an important role in thyroid follicular cell oncogenesis. Copyright 2010 IMSS. Published by Elsevier Inc. All rights reserved.
Authors: Rachel D Zamoiski; Elizabeth K Cahoon; D Michal Freedman; Martha S Linet; Cari M Kitahara Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-02 Impact factor: 4.254
Authors: G Muscogiuri; G Tirabassi; G Bizzaro; F Orio; S A Paschou; A Vryonidou; G Balercia; Y Shoenfeld; A Colao Journal: Eur J Clin Nutr Date: 2014-12-17 Impact factor: 4.016
Authors: Marissa Penna-Martinez; Elizabeth Ramos-Lopez; Julienne Stern; Heinrich Kahles; Nora Hinsch; Martin-Leo Hansmann; Ivan Selkinski; Frank Grünwald; Christian Vorländer; Wolf O Bechstein; Stefan Zeuzem; Katharina Holzer; Klaus Badenhoop Journal: Thyroid Date: 2012-06-12 Impact factor: 6.568
Authors: B Balla; B Tobiás; J P Kósa; J Podani; P Horváth; Z Nagy; J Horányi; B Járay; E Székely; L Krenács; K Árvai; M Dank; Z Putz; B Szabó; B Szili; Z Valkusz; B Vasas; G Győri; P Lakatos; I Takács Journal: J Endocrinol Invest Date: 2014-09-09 Impact factor: 4.256
Authors: Minjing Zou; Essa Y Baitei; Huda A BinEssa; Futwan A Al-Mohanna; Ranjit S Parhar; René St-Arnaud; Shioko Kimura; Catrin Pritchard; Ali S Alzahrani; Abdullah M Assiri; Brian F Meyer; Yufei Shi Journal: Cancer Res Date: 2017-02-27 Impact factor: 12.701
Authors: Grégoire B Morand; Sabrina Daniela da Silva; Michael P Hier; Moulay A Alaoui-Jamali Journal: Front Oncol Date: 2014-11-04 Impact factor: 6.244